

Oritavancin Activity Against Gram-positive Isolates Responsible for Intra-Abdominal Infections in Europe and Surrounding Regions During 2015-2019

Cecilia G. Carvalhaes, Dee Shortridge, Jennifer M. Streit, Rodrigo Mendes

Objective

To evaluate the activity of oritavancin, a lipoglycopeptide antibiotic indicated for acute bacterial skin and skin structure infection (ABSSSI), against Gram-positive pathogens causing intra-abdominal infection (IAI) in European hospitals and adjacent regions.

Methods

- “ A total of 972 Gram-positive isolates were collected from patients with IAI (1/patient) in 2015-2019.
- “ Isolates were recovered from 29 hospitals located in 11 European countries (Belgium, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Spain, Sweden, United Kingdom), Israel, and Turkey.
- “ Isolates were identified by standard phenotypic test and MALDI-TOF and susceptibility tested by CLSI reference broth microdilution.
- “ EUCAST interpretive criteria were applied to oritavancin and comparators.



Results

Acknowledgements

Contact